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INTRODUCTION: Administration of the NO inhibitor Nwð-nitro-L-arginine methyl ester (NAME) and a high-salt diet (HS)
promotes severe albuminuria and renal injury, which regresses upon discontinuation of treatments.
OBJECTIVE: We investigated whether these changes reappear after reinstitution of HS, and whether they are prevented by
treatment with the antilymphocyte agent mycophenolate mofetil (MMF) or the AT-1 receptor blocker losartan (L). Adult male
Munich-Wistar rats received NAME and HS. A control Group (C) received only HS. After 20 days, rats receiving HS and NAME
exhibited severe hypertension and albuminuria. After a 30-day recovery period, hypertension was attenuated and albuminuria had
virtually disappeared.
MATERIAL AND METHODS: Rats were then distributed among the following groups: HS, receiving HS; NS, receiving a
normal salt (NS) diet; HS-MMF, receiving HS and MMF; HS-LOS, receiving HS and L; HS-HDZ, receiving HS and hydralazine
(HDZ). Sixty days later, NS rats showed only slight albuminuria and renal damage or inflammation. In contrast, HS rats developed
severe hypertension, marked glomerulosclerosis with interstitial expansion and renal infiltration by macrophages and angiotensin
II-positive cells. The group treated with losartan had lowered blood pressure and a lack of albuminuria or renal injury. MMF
provided similar protection without altering blood pressure, suggesting a nonhemodynamic effect, a hypothesis reinforced by the
finding that HDZ lowered blood pressure without preventing renal injury.
RESULTS: These results indicate that treatment with HS and NAME predisposes to the development of hypertension and renal
injury upon salt overload, characterizing a new model of chronic nephropathy. CONCLUSION: The response to MMF or L, but
not HDZ, suggests a key role for inflammatory rather than hemodynamic factors.
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INTRODUCTION
Chronic nitric oxide inhibition has been amply utilized
as a model of hypertension and chronic renal injury.1-3 Pre-
vious observations4,5,6 suggested that these abnormalities
were reversible upon cessation of treatments. However, re-
cent observations indicate that this recovery is incomplete,
and that the persistence of several inflammatory elements
heralds the development of chronic kidney disease and pro-
gressive renal insufficiency in these animals.5
Dietary salt overload is known to exacerbate renal in-
jury initiated by a host of other mechanisms.4,7 The
mechanisms responsible for this effect are unclear. Al-
though systemic hypertension is an obvious possibility,
increased salt intake may dose-dependently promote re-
nal injury even without a corresponding blood pressure
variation,8 suggesting that nonhemodynamic factors, per-
haps directly related to extracellular volume expansion,
intervene in this process. Inflammatory mechanisms, such
as activation of the NF-k-B system,9,10 lymphocyte and
macrophage infiltration11 exacerbated production of
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TGFβ12 and anomalous production of angiotensin II (Ang
II)10 in the renal parenchyma are possible mediators of this
effect of salt excess.
Rechallenging animals with a salt-rich diet after termi-
nation of NO blockade has been shown to promote the re-
appearance of hypertension and a worsening of renal in-
jury.6 Treatment with mycophenolate mofetil (MMF), an
antilymphocyte agent, during the early NO inhibition phase
largely prevents the development of hypertension and re-
nal injury by salt overload after NO inhibition is removed,6
suggesting that inflammatory mechanisms play a role in
this process. However, the effects of late treatment with
MMF or suppressors of the renin-angiotensin system have
not been evaluated.
In the present study, we examined the behavior of rats
subjected to short-term treatment with NAME and salt over-
load after only the latter was reintroduced a few weeks later.
To assess the role of hypertension and inflammatory phe-
nomena in the development of hypertension and renal in-
jury induced by reinstitution of sodium overload, we treated
these animals with MMF, suppressors of the RAS system
or hydralazine. This experimental design allowed us to
characterize a new model of chronic nephropathy which,
unlike the chronic NO inhibition model from which it de-
rives, is characterized by low mortality and nonprogressive
hypertension, yet courses with severe albuminuria, culmi-
nating with the establishment of well defined glomerulo-
sclerosis and renal interstitial injury.
METHODS
Fifty-six adult male Münich-Wistar rats (initially weigh-
ing 200 to 260 g) obtained from a local facility were used
in this study. The animals were maintained at 23±1°C on
a 12/12 hours light/dark cycle, and were given free access
to tap water and either a normal-salt diet (NS (0.5% Na))
or high-salt diet (HS (3.2% Na)). Both diets contained 22%
protein and were purchased from Harlan Teklad (Troy, IL).
All experimental procedures were approved by the local
Research Ethics Committee and conformed strictly to our
institutional guidelines and to international standards for
the manipulation and care of laboratory animals.
Experimental groups and experimental protocol
The experimental protocol is described in schematic
form in Table 1. During the initial part of the protocol
(Phase 1), rats received HS chow and the NO synthase in-
hibitor Nω-nitro-L-arginine methyl ester (NAME) in their
drinking water at a concentration of 100 mg/ L, correspond-
ing to a daily intake of 25 mg/kg. At the end of this 20-
day period, all treatments ended and rats received NS for
the next 30 days (recovery period). Rats were then distrib-
uted among five experimental groups according to the treat-
ment received from this time until the end of the study, 60
days later (Phase 2), as is schematically described in Ta-
ble 1. Group HS (n=12) received HS only. Group NS
(n=10) received NS only. Group HS-MMF (n= 8) received
HS and the antilymphocyte agent, mycophenolate mofetil
(MMF) at 10 mg/kg by gavage once daily. Group HS-LOS
(n=6) was treated as the preceding group, but received the
AT-1 receptor blocker losartan potassium, 50 mg/kg /day
in the drinking water, instead of MMF. Group HS-HDZ
(n=8) was treated as the two preceding groups, but received
hydralazine, 6 mg/kg in the drinking water, instead of
losartan or MMF. This group served as a blood pressure
control for the HS-LOS group, in which blood pressure was
brought to near normal levels. A control Group (C) of 12
rats received HS and no NAME for the first 20 days (Phase
1), and was then switched to NS for the following 30 days,
as for all other groups. The control animals were then given
HS until the end of the study, 60 days later (Phase 2). This
group served as a time control.
Tail-cuff pressure (TCP) and urinary albumin excretion
rate (U
albV) were measured immediately before treatments
with HS and NAME or HS alone were initiated (Day 0),
at the end of Phase 1 (Day 20), 30 days after these treat-
ments had been terminated (end of the recovery period) and
60 days later (end of Phase 2).
Measurement of tail-cuff pressure (TCP) and
albuminuria (U
albV)
TCP was estimated by a tail-cuff method using a blood
pressure analysis system (Visitech Systems, USA). Animals
were conditioned 2 or 3 times before measurements were
taken. Twenty-four-hour urine was collected in individual
metabolic cages for assessment of albumin concentration
by radial immunodiffusion.13
Table 1 - Schematic description of experimental groups
TREATMENT
GROUP N Day 0-20 Day 21-50 Day 51-110
C 12 HS NS HS
HS 10 HS+NAME NS HS
NS 12 HS+NAME NS NS
HS-MMF 8 HS+NAME NS HS+MMF
HS-LOS 6 HS+NAME NS HS+LOS
HS-HDZ 8 HS+NAME NS HS+HDZ
Abbreviations: C, Control; HS, High-salt; NS, normal salt, NAME, Nwð-
nitro-L-arginine methyl ester; MMF, Mycophenolate mofetil; LOS,
Losartan; HDZ, Hydralazine.
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Morphological analysis
At the end of the study, kidneys were perfusion-fixed
at the measured arterial pressure with Duboscq-Brasil so-
lution after a brief washout with saline. After fixation, the
renal tissue was weighed and 2 midcoronal sections were
postfixed in buffered 4% formaldehyde solution. The ma-
terial was then embedded in paraffin for assessment of
glomerular and renal cortical interstitial injury and for im-
munohistochemical identification of macrophages and of
cells staining positively for angiotensin II.
Histomorphometry
2–3 mm thick sections were stained with periodic acid-
Schiff or Masson trichrome. All morphometric evaluations
were performed in a blinded manner by a single observer. The
frequency of glomeruli exhibiting sclerotic lesions (GS) was
estimated by consecutive examination of at least 300 glomeruli
at 200´. The fraction of the renal cortex occupied by intersti-
tial tissue was quantified in Masson-stained sections by a point
counting technique 14 in 25 consecutive microscopic fields, at
a final magnification of 100´ under a 176-point grid.
Immunohistochemistry
Immunohistochemical procedures were described in de-
tail previously 15. Briefly, macrophages and cells positive for
AngII were detected by an indirect streptavidin-biotin alka-
line phosphatase technique. For macrophage detection, a
monoclonal mouse anti-rat ED-1 antibody (Serotec, Oxford,
United Kingdom) was used. AngII-positive cells were de-
tected by a monoclonal rabbit anti-human AngII antibody
(Peninsula Laboratories, San Carlos, CA). The density of re-
nal interstitial infiltration by macrophages (Mf) and AngII-
positive cells was evaluated in a blinded manner at 250x
magnification and expressed as cells/mm2.
Statistics
One-way analysis of variance with pairwise compari-
sons according to the Newman-Keuls method was used in
this study to assess the statistical significance of differences
between groups. Since the distribution of U
albV was strongly
non-Gaussian, these data underwent log transformation
prior to statistical analysis. p values of 0.05 or less were
considered significant.
RESULTS
Body growth was similar among groups, although body
weight at the end of the study was slightly higher in Group
HS compared to the remaining groups (data not shown).
As described previously,4 TCP was markedly elevated af-
ter 20 days in all groups receiving HS and NAME treat-
ments (Fig. 1A). This increase was accompanied by dete-
rioration of glomerular barrier function, as indicated by
massive albuminuria (Fig. 1B), which reached values 100-
fold higher than baseline. No changes in TCP or U
albV were
noted in control rats (Group C).
Thirty days after the combined HS and NAME treat-
ment ended (Group NS), TCP decreased to a similar ex-
tent in all groups, although the values for each group re-
mained significantly higher than for Group C (Fig. 1A).
Albuminuria was drastically reduced in all treated groups
after HS and NAME were withdrawn (Fig.1B), bringing the
U
albV levels in each group to insignificant values.
By the end of Phase 2 (i.e., sixty days after HS treat-
ment was reinstituted), Group HS again exhibited very se-
Figure 1 - Time course of tail-cuff pressure, TCP (A), and urine albumin
excretion rate, U
albV (B), in Group C (open circles), NS (open squares), HS
(closed circles), HS-MMF (closed squares) , HS-LOS (closed triangles) and
HS-HDZ (open diamonds). Results of statistical analyses of differences
among groups at the end of the study (Day 110) are shown below the
respective panels.
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vere hypertension, reaching TCP levels comparable to those
observed on Day 20 of Phase 1 (Fig. 1A). Likewise, albu-
minuria (Fig. 1B) rose to levels similar to the peak values
observed during Phase 1, indicating the development of
substantial glomerular injury in these rats. In contrast, blood
pressure had decreased slightly in Group NS at the end of
the study. Accordingly, no elevation in U
albV was observed
in this group at the end of phase 2 (Fig. 1B).
Treatment with MMF attenuated hypertension in Group
HS-MMF, although TCP increased from the values observed
at the beginning of MMF treatment, reaching levels signifi-
cantly higher than baseline (Fig. 1A). In contrast, both
losartan (Group HS-LOS) and hydralazine (Group HS-LOS)
treatments of rats receiving HS brought TCP to levels indis-
tinguishable from those observed in Group C. However, the
effects of the treatments on U
albV were clearly different from
the effects on TCP, as the rise in albuminuria was completely
prevented by losartan, strongly attenuated by MMF and only
partially prevented by hydralazine (Fig. 1B).
Morphological analysis performed at the end of the study
showed that rats rechallenged with HS treatment developed
severe renal injury, with 10% of glomeruli examined show-
ing sclerotic lesions (Fig. 2A), while the fraction of the re-
nal cortical area occupied by interstitial tissue increased to
nearly 6%, as opposed to 0.6% in group C (Fig. 2B). In rats
receiving NS during Phase 2 (Group NS), renal injury was
not different from baseline. Treatment with either MMF or
losartan prevented the development of glomerular and in-
terstitial injury, both of which remained comparable to base-
line (Figs 2A and 2B). Despite its effect on blood pressure,
hydralazine treatment during Phase 2 only attenuated the fre-
quency of sclerotic glomeruli and the percent interstitial area,
which remained elevated compared to baseline.
Immunohistochemical analysis of the renal tissue at the
end of the study showed intense renal macrophage infil-
tration, especially in interstitial areas (Fig. 3A), in rats pre-
conditioned with HS and NAME and treated with late HS
(Group HS). In contrast, renal macrophages were rare and
sparse in rats treated with NS during Phase 2 (Group NS)
. Renal macrophage infiltration was equally prevented at
this phase by treatment with either MMF or losartan, but
not by hydralazine. A similar pattern was observed for
AngII, which was densely expressed at the interstitial area
in Group HS, but not in Group NS (Fig. 3B). Once again,
treatment with either MMF or losartan, but not with hy-
dralazine, limited the renal interstitial expression of AngII
in rats receiving HS during Phase 2.
DISCUSSION
As shown previously,4,5 short-term chronic NO inhibi-
tion, with simultaneous sodium overload, promoted severe
hypertension and massive albuminuria. There was a quick
but incomplete regression of hypertension upon withdrawal
of the treatments, as TCP remained above baseline. The
regression of albuminuria was more pronounced, with U
albV
falling to levels indistinguishable from baseline. This sug-
gests that the kidney is able to recover from the initial in-
sult, as occurs in most cases of postinfectious glomerulone-
phritis, for example. However, the regression of renal in-
jury in this model is incomplete. Previous observations of
this model 5 showed that the density of cells staining posi-
tively for AngII never returned to baseline and that these
rats exhibited progressive albuminuria and hypertension, as
well as severe glomerular and interstitial injury, when fol-
lowed for an additional 6 months. These observations sug-
gest that even a short-term treatment with an NO inhibiter
in association with salt overload can lead to subtle changes
that culminate in the insidious development of chronic kid-
ney disease. The mechanisms underlying why low-grade
Figure 2 - Frequency of glomeruli with segmental sclerotic lesions (GS,
panel A) and percent of cortical area occupied by interstitial tissue (%INT,
panel B) at the end of the study (Day 110). Results of statistical analyses are
shown below the respective panels.
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inflammation and unchecked production of AngII persist
and progress toward serious damage to the renal paren-
chyma long after NO inhibition is ended are unclear. One
attractive possibility is that these processes are triggered
and/or maintained by residual damage to the preglomerular
microvessels, which undergo severe constriction and wall
thickening during NO inhibition,1,2 although solid evidence
in favor of this possibility is lacking.
Reinstitution of HS, but not NAME, treatment one
month after both treatments had been interrupted led to a
reappearance of hypertension that eventually reached lev-
els similar to the peak values observed during initial HS/
NAME treatment. Likewise, albuminuria, which had de-
creased to levels not far from baseline one month after HS
and NAME treatment was stopped, rose to levels similar
to those attained by the end of the initial HS/NAME treat-
ment, while only a slight increase in albuminuria and blood
pressure was seen in rats receiving a regular salt diet. These
observations indicate that previous treatment with HS and
NAME not only leads to insidious progressive chronic dis-
ease, but also predisposes to the rapid development of hy-
pertension and renal injury upon salt overload.
Although the administration of a salt-rich diet to oth-
erwise normal animals is not clearly associated with overt
hypertension or nephropathy, salt overload is known to ex-
acerbate renal injury initiated by other mechanisms, such
as diabetes,12 5/6 renal ablation16 and chronic NO inhibi-
tion.4 The intimate mechanisms responsible for this effect
are unclear. Salt overload may cause renal damage as a re-
sult of direct hemodynamic changes, such as hypertension
or extracellular volume expansion. However, observations
made in rats with genetic hypertension indicated that the
adverse effects of excess sodium in these rats can occur
with minimal blood pressure elevation.8 Accordingly, acute
intravenous sodium overload was shown to promote renal
activation of the NF-k-B system, as well as increased pro-
duction of TGF-β and RANTES, without changes in MAP
or GFR.10 These observations suggest that inflammatory
mechanisms may mediate salt-induced renal injury in ad-
dition to, or in lieu of, hemodynamic stress.
Angiotensin II is likely to mediate at least part of the
deleterious effects of excess sodium.5,6,10,17 This appears to
be a paradox since salt overload would be expected to sup-
press circulating renin and angiotensin II. However, local
production of angiotensin II also occurs at the diseased re-
nal tissue, as shown in several models of chronic kidney
disease, even when salt intake is increased.6,15,17 In rats re-
ceiving HS/NAME treatment, AngII was shown to abound
in areas of renal interstitial inflammation.6,17 Accordingly,
AngII appeared in inflamed renal interstitial areas in Group
HS at the end of the present study, after these rats had re-
ceived HS for several weeks. Collectively, these findings
are consistent with the view that locally produced AngII
is independent of the usual physiologic control, as deter-
mined by the needs of sodium processing by the organism.
Rather, local AngII appears to correlate with the presence
of macrophages, and may participate in the inflammatory
process associated with chronic kidney disease. Accord-
ingly, abundant evidence now indicates that AngII can in-
fluence several events known to be involved in chronic in-
flammation, such as lymphocyte activation,18 expression of
adhesion molecules19 and inflammatory mediators,20 pro-
liferation of a host of resident and inflammatory cells and
production of stimulators of fibrogenesis.21
Suppression of the RAS with chronic losartan during
Phase 2 effectively prevented both hypertension and renal
injury, as shown previously in multiple studies of clinical
and experimental CKD. The beneficial effect of losartan
could be due solely to its hemodynamic action, since
renoprotection was associated with near normalization of
Figure 3 - A – Density (in cells/mm2) of renal interstitial infiltration by
macrophages (MAC, panel A) and cells staining positively for AngII (AngII+,
panel B) at the end of the study (Day 110). Results of statistical analyses are
shown below the respective panels.
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blood pressure. However, the favorable effect of losartan
was not duplicated by hydralazine, which promoted only
partial renoprotection, although blood pressure was main-
tained at baseline levels with either treatment, suggesting
that systemic hypertension was not a decisive factor in the
pathogenesis of renal injury. Since glomerular pressure was
not measured in this study, the possibility that glomerular
hypertension persisted in hydralazine-treated rats despite
a normalization of blood pressure cannot be excluded.
However, treatment with MMF, an antilymphocyte drug
possessing several anti-inflammatory effects, prevented re-
nal injury as effectively as losartan therapy, even though
blood pressure remained elevated in MMF-treated rats.
These observations are consistent with previous findings
that MMF limits renal inflammation and chronic injury in
models such as 5/6 renal ablation,22,23 streptozotocin-in-
duced diabetic nephropathy24 and chronic NO inhibition.25
Taken together, these data indicate that both blockade of
the AT-1 receptor and inhibition of inflammatory events
constitute effective strategies to prevent the progression of
CKD in rats rechallenged with HS after short-term HS and
NAME treatment. Whether the association of losartan and
MMF would afford more complete renoprotection was not
addressed in the present study. However, it should be noted
that the association of MMF with an AT-1 receptor blocker
or an ACE inhibitor prevented CKD much more effectively
than either monotherapy in the renal ablation model.26-28
In summary, the present observations corroborate pre-
vious findings that short-term treatment with HS and
NAME leads to reversible hypertension and albuminuria.
In addition, we show that reintroduction of HS after a re-
covery period causes progressive renal injury and inflam-
mation, which can be prevented by treatment with losartan
or MMF. Late HS administration following short-term treat-
ment with HS and NAME constitutes a suitable new model
of CKD that is considerably less aggressive than 5/6 renal
ablation or sustained inhibition of NO synthesis, yet pos-
sesses a progressive nature that allows for detailed exami-
nation of pathogenic factors, as well as evaluation of the
renoprotective effects of pharmacological strategies.
RESUMO
Mattar AL, Machado FG, Fujihara CK, Malheiros DMAC,
Zatz R. Hipertensão persistente e lesão renal progressiva
induzidas por sobrecarga de sal após inibição temporária
do óxido nítrico. Clinics.2007;62(6):749-56.
INTRODUÇÃO: A administração de Nω-nitro-L-arginina
metiléster (NAME), um inibidor da produção de NO, com
dieta rica em sal (HS) promove albuminúria e dano renal
graves, reversíveis ao interromperem-se os tratamentos.
OBJETIVO: Investigamos se tais alterações recrudescem
ao reinstituir-se a HS e se são prevenidas pelo micofenolato
mofetil (MMF), um agente antilinfócito, ou losartan, um
bloqueador do receptor AT-1.
MATERIAL E MÉTODOS: Ratos Münich-Wistar
machos adultos receberam NAME e HS. Um grupo controle
(C) recebeu apenas HS. Após 20 dias, os ratos que
receberam HS e NAME exibiam hipertensão e albuminúria
graves. Após recuperação de 30 dias, a hipertensão atenuou-
se e a albuminúria praticamente desapareceu. Formaram-
se então os grupos: HS, recebendo HS; NS, recebendo dieta
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normal em sal (NS); HS-MMF, recebendo HS e MMF; HS-
LOS, recebendo HS e losartan; HS-HDZ, recebendo HS e
hidralazina. Após sessenta dias os ratos NS tinham
albuminúria e dano/inflamação renal apenas discretos. Já
os ratos HS desenvolveram hipertensão e glomerulosclerose
acentuadas, expansão intersticial e infiltração renal por
macrófagos e células positivas para angiotensina II.
Losartan baixou a pressão arterial e preveniu albuminúria
e lesão renal. MMF proporcionou proteção semelhante sem
alteração pressórica, sugerindo a ação de mecanismos não
hemodinâmicos, hipótese reforçada pelo achado de que a
HDZ baixou a pressão arterial sem prevenir a nefropatia.
RESULTADOS: Esses resultados indicam que o tratamento
com HS e NAME predispõe ao desenvolvimento de
hipertensão e lesão renal induzidos por excesso de sal,
caracterizando um novo modelo de nefropatia crônica.
CONCLUSÃO: A resposta ao MMF ou losartan, mas não
à hidralazina, sugere o predomínio de fatores inflamatórios.
UNTERMOS: Doença crônica do rim. Micofenolato
mofetil. Angiotensina. AT-1 receptor bloqueador. Excesso
de sal.
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